ethyl 4-bromo-3-formylbenzoate | 1219935-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-bromo-3-formylbenzoate
• 英文别名: 4-Bromo-3-formyl-benzoic acid ethyl ester
• CAS: 1219935-96-2
• 化学式: C₁₀H₉BrO₃
• 分子量: 257.084
• InChiKey: ACNHKCARYBQIEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-bromo-3-formylbenzoate 在 palladium diacetate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Exploiting the π-Acceptor Properties of Carbene-Stabilized Phosphorus Centered Trications [L₃P] ³⁺: Applications in Pt(II) Catalysis

  摘要：

  Reaction of tris(dimethylaminocyclopropenium) substituted phosphine 1 with K2PtCl4 afforded the bench stable complex 3 which upon treatment with Ag[CB11H6Cl6] turned out to be an excellent catalyst for the transformation of a variety of ortho-biaryl substituted alkynes into polycyclic homo- and heteroarenes of different size, shape, and curvature through a 6-endo-dig cyclization. This constitutes the first example ever reported of using a P-1-centered trication as ligand in catalysis. The strong pi-acceptor character of 1 that derives from its three positive charges substantially increases the intrinsic pi-acidity of Pt in complex 1.PtCl2 and dramatically enhances its ability to activate pi-systems toward nucleophilic attack. As a consequence, a remarkable acceleration of the model transformation is observed when compared with other classical pi-acceptor ligands such as P(OPh)(3) or P(C6F5)(3). Moreover, the employment of 1 as ligand also expands the scope of this reaction to previously inaccessible substitution patterns. Kinetic studies and deuterium labeling experiments as well as density functional theory (DFT) calculations were performed in order to explain these findings.

  DOI：

  10.1021/ja306947m
• 作为产物：
  描述：

  ethyl 3-dibromomethyl-4-bromobenzoate 在 silver nitrate 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 ethyl 4-bromo-3-formylbenzoate
  参考文献：
  名称：

  HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

  摘要：

  本文描述了PGD2受体拮抗剂化合物。还描述了包括本文所述化合物的药物组合物，以及使用这些PGD2受体拮抗剂，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症的方法。

  公开号：

  US20100081673A1

文献信息

• Bis(cyclopropenium)phosphines: Synthesis, Reactivity, and Applications
  作者：Gerlinde Mehler、Pawel Linowski、Javier Carreras、Alessandro Zanardi、Jonathan W. Dube、Manuel Alcarazo

  DOI：10.1002/chem.201601759

  日期：2016.10.17

  substituent pattern on the catalytic activity of the metal complexes thereof derived is also studied. Whereas sterically demanding biaryl groups directly attached to the phosphorus atom seem to facilitate elementary steps such as the product release from the catalyst, long chain dialkylamino groups on the cyclopropenium units maximize the catalysts solubility and, thus, allow the use of typical apolar

  据报道，制备一组双（环丙烯）取代的膦的简单方法。由于它们的修饰性质，这些配体表现出出色的π受体特性。还研究了配体取代基图案对其衍生的金属配合物的催化活性的影响。尽管直接与磷原子连接的空间要求的联芳基似乎促进了基本步骤（例如产物从催化剂中释放），但环丙烯单元上的长链二烷基氨基基团最大程度地提高了催化剂的溶解度，因此允许使用典型的非极性溶剂，例如甲苯。重要的是，所有制备的新配体都可以在空气中轻松处理。最后，证明了新制备的双膦膦在氢芳基化反应中的影响。尤其是，[b ]呋喃烷和天然存在的萘衍生物，例如CalanquinoneC。
• Heteroaryl antagonists of prostaglandin D2 receptors
  申请人：Panmira Pharmaceuticals, LLC

  公开号：US08049015B2

  公开（公告）日：2011-11-01

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。同时还描述了包括上述化合物的药物组合物，以及使用这些PGD2受体拮抗剂，单独或与其他化合物联合使用，治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症的方法。
• US8049015B2
  申请人：——

  公开号：US8049015B2

  公开（公告）日：2011-11-01
• [EN] HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS<br/>[FR] ANTAGONISTES HÉTÉROARYLIQUES DES RÉCEPTEURS DE PROSTAGLANDINE D2
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2010037054A2

  公开（公告）日：2010-04-01

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
• Exploiting the π-Acceptor Properties of Carbene-Stabilized Phosphorus Centered Trications [L₃P] ³⁺: Applications in Pt(II) Catalysis
  作者：Javier Carreras、Mahendra Patil、Walter Thiel、Manuel Alcarazo

  DOI：10.1021/ja306947m

  日期：2012.10.10

  Reaction of tris(dimethylaminocyclopropenium) substituted phosphine 1 with K2PtCl4 afforded the bench stable complex 3 which upon treatment with Ag[CB11H6Cl6] turned out to be an excellent catalyst for the transformation of a variety of ortho-biaryl substituted alkynes into polycyclic homo- and heteroarenes of different size, shape, and curvature through a 6-endo-dig cyclization. This constitutes the first example ever reported of using a P-1-centered trication as ligand in catalysis. The strong pi-acceptor character of 1 that derives from its three positive charges substantially increases the intrinsic pi-acidity of Pt in complex 1.PtCl2 and dramatically enhances its ability to activate pi-systems toward nucleophilic attack. As a consequence, a remarkable acceleration of the model transformation is observed when compared with other classical pi-acceptor ligands such as P(OPh)(3) or P(C6F5)(3). Moreover, the employment of 1 as ligand also expands the scope of this reaction to previously inaccessible substitution patterns. Kinetic studies and deuterium labeling experiments as well as density functional theory (DFT) calculations were performed in order to explain these findings.